Temozolomide

Temozolomide (NSC 362856) is an oral active DNA alkylating agent that crosses the blood-brain barrier. Temozolomide is also a proautophagic and proapoptotic agent. Temozolomide is effective against tumor cells that are characterized by low levels of O6-alkylguanine DNA alkyltransferase (OGAT) and a functional mismatch repair system. Temozolomide has antitumor and antiangiogenic effects[1][2].

Product Specifications

CAS Number

[85622-93-1]

Product Name Alternative

NSC 362856; CCRG 81045; TMZ

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335, H340, H350, H360

Target

Apoptosis; Autophagy; DNA Alkylator/Crosslinker

Type

Reference compound

Related Pathways

Apoptosis; Autophagy; Cell Cycle/DNA Damage

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/Temozolomide.html

Purity

99.98

Solubility

DMSO : 20.83 mg/mL (ultrasonic) |H2O : 2.86 mg/mL (ultrasonic)

Smiles

O=C(C1=C(N2C=N1)N=NN(C)C2=O)N

Molecular Formula

C6H6N6O2

Molecular Weight

194.15

Precautions

H302, H315, H319, H335, H340, H350, H360

References & Citations

[1]Tentori L, et al. Combined treatment with temozolomide and poly (ADP-ribose) polymerase inhibitor enhances survival of mice bearing hematologic malignancy at the central nervous system site. Blood. 2002 Mar 15;99 (6) :2241-4.|[2]Perazzoli G, et al. Temozolomide Resistance in Glioblastoma Cell Lines: Implication of MGMT, MMR, P-Glycoprotein and CD133 Expression. PLoS One. 2015 Oct 8;10 (10) :e0140131.|[3]Mathieu V, et al. Combining Anti-Human VEGF with temozolomide increases the antitumor efficacy of temozolomide in a human glioblastoma orthotopic xenograft model. Neoplasia. 2008 Dec;10 (12) :1383-92.